Table 3.
Biomarker Analyses in Neuroblastomas*
| Tumor Sample | Time Points Analyzed | Sequencing Analysis | Distinct Paired Tags Analyzed | Physical Coverage | Somatic Rearrangements | Mutant Template Molecules in Serum or Plasma (per mL) | Mutant Template Molecules in Circulating Tumor Cells (per mL) | Post-MRD Therapy Outcome |
|---|---|---|---|---|---|---|---|---|
| NB02C | At Diagnosis (1) | High Coverage Whole-Genome | 154,389,649 | 15 | 16 | 136 | 40 | Not Enrolled |
| NB04C | At Diagnosis (1) | High Coverage Whole-Genome | 155,886,351 | 16 | 1 | 48,700 | 2,020 | Not Enrolled |
| NB03C | At Diagnosis (1) | MYCN Locus Capture | 4,048,315 | 911 | 2 | 185,000 | 30,200 | Not Enrolled |
| NB2885T | MRD Therapy (7) | Low Coverage Whole-Genome | 131,086,400 | 10 | 7 | < 1.0 – 16.6 | ND | Died of Disease |
| NB2870T | MRD Therapy (2) | Low Coverage Whole-Genome | 62,151,315 | 5 | 2 | 811–8,450 | ND | Died of Disease |
| NB2464T | MRD Therapy (7) | Low Coverage Whole-Genome | 61,486,874 | 5 | 1 | < 0.7 | ND | Alive at Follow-up |
| NB6321T | MRD Therapy (3) | Low Coverage Whole-Genome | 134,781,854 | 10 | 14 | < 0.7 | ND | Alive at Follow-up |
*
Distinct paired tags analyzed is based on unique start sites for each paired-end read; Physical coverage is the number of paired reads expected to span any location in a haploid genome; chr2:15.5Mb–16.5Mb was considered for the MYCN locus capture sequencing analysis. Where multiple time points were available (as indicated by the number of samples analyzed in parentheses), the range of circulating tumor DNA is shown. ND indicates the sample was not available; MRD, minimal residual disease.